Literature DB >> 15241745

Vascular biology in uremia: insights into novel mechanisms of vascular injury.

Ziyad Al Aly1, John C Edwards.   

Abstract

Cardiovascular disease is the leading cause of death in patients with end-stage renal disease. Although the prevalence of traditional atherosclerotic risk factors is increased in patients with chronic kidney disease, these traditional risk factors alone do not seem to account for the increased cardiovascular mortality. It has been proposed that additional risk factors may play a role in vascular injury. Among nontraditional risk factors, chronic inflammation, oxidative stress, and vascular calcification have been implicated in the accelerated athersclerosis of chronic kidney disease. Uremia is a proinflammatory state. Elevated levels of the proinflammatory cytokine interleukin-6 and suppressed levels of the anti-inflammatory cytokine interleukin-10 are present in chronic kidney disease and have been implicated in accelerated atherosclerosis. Uremia also results in increased oxidative stress. Asymmetric dimethyl arginine and myeloperoxidase may be critical mediators of the endothelial damage that results from oxidative stress. Finally, the uremic milieu seems to promote vascular calcification. The abundance of proinflammatory cytokines, the possible deficiency in calcification inhibitory proteins and the high phosphorus that are often present in uremia contribute to vascular calcification. Smooth muscle cells in calcifying lesions undergo phenotypic changes and molecular reprogramming that are reminiscent of endochondral bone formation during embryogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15241745     DOI: 10.1053/j.arrt.2004.04.006

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  7 in total

1.  The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD.

Authors:  Giovana S Di Marco; Stefan Reuter; Uta Hillebrand; Susanne Amler; Maximilian König; Etienne Larger; Hans Oberleithner; Eva Brand; Hermann Pavenstädt; Marcus Brand
Journal:  J Am Soc Nephrol       Date:  2009-07-16       Impact factor: 10.121

2.  Particulate Matter Air Pollution and the Risk of Incident CKD and Progression to ESRD.

Authors:  Benjamin Bowe; Yan Xie; Tingting Li; Yan Yan; Hong Xian; Ziyad Al-Aly
Journal:  J Am Soc Nephrol       Date:  2017-09-21       Impact factor: 10.121

Review 3.  Clinical imaging of vascular disease in chronic kidney disease.

Authors:  Alan A Sag; Adrian Covic; Gerard London; Marc Vervloet; David Goldsmith; Jose Luis Gorriz; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2016-02-22       Impact factor: 2.370

4.  Rate of kidney function decline associates with mortality.

Authors:  Ziyad Al-Aly; Angelique Zeringue; John Fu; Michael I Rauchman; Jay R McDonald; Tarek M El-Achkar; Sumitra Balasubramanian; Diana Nurutdinova; Hong Xian; Kevin Stroupe; Kevin C Abbott; Seth Eisen
Journal:  J Am Soc Nephrol       Date:  2010-10-14       Impact factor: 10.121

5.  Microparticles from Hyperphosphatemia-Stimulated Endothelial Cells Promote Vascular Calcification Through Astrocyte-Elevated Gene-1.

Authors:  Yazhou Xiang; Yingjie Duan; Zhong Peng; Hong Huang; Wenjun Ding; En Chen; Zilong Liu; Chengyun Dou; Jianlong Li; Jihong Ou; Qingsong Wan; Bo Yang; Zhangxiu He
Journal:  Calcif Tissue Int       Date:  2022-02-23       Impact factor: 4.000

6.  Poly(ADP-ribose) polymerase 1 accelerates vascular calcification by upregulating Runx2.

Authors:  Cheng Wang; Wenjing Xu; Jie An; Minglu Liang; Yiqing Li; Fengxiao Zhang; Qiangsong Tong; Kai Huang
Journal:  Nat Commun       Date:  2019-03-13       Impact factor: 14.919

7.  The clinical effectiveness and safety of traditional Chinese medicine uremic clearance granule combined with high-flux hemodialysis in the treatment of uremic pruritus: A protocol for systematic review and meta analysis.

Authors:  Ya-Fei Bai; Chun-Li Wang; Ming-Zhi Xu; Ming-Jiao Pan; Qing-Yi Sun; Ru-Man Chen
Journal:  Medicine (Baltimore)       Date:  2021-06-25       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.